FDA grants landmark approval for Pixclara — the first FDA-approved FET-PET imaging drug for brain cancer
The United States Food and Drug Administration (FDA) has approved Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) New Drug Application (NDA) for Pixclara (floretyrosine F 18 / 18F-FET), making it the first and only FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer). The drug is indicated for use with positron emission tomography (PET) to differentiate recurrent or progressive glioma from treatment-related change in adults and paediatric patients aged 1 month and older.
The approval addresses a condition with considerable scale. Gliomas account for approximately 30% of all brain and central nervous system (CNS) tumours and around 80% of all malignant brain tumours, with approximately 24,000 new cases diagnosed in the U.S. each year.
When big ASX news breaks, our subscribers know first
Understanding glioma imaging — and why FET-PET matters
Glioma is the most common form of CNS cancer, and managing it presents a persistent diagnostic challenge. After treatment, physicians must determine whether changes visible on imaging represent true tumour recurrence or progression versus treatment-related change, a distinction that complements the role of MRI.
FET-PET imaging addresses this gap. Pixclara is administered intravenously and targets membrane transport proteins known as L-type amino acid transporters (LAT1 and LAT2). The fluorine-18 radioactive label then emits energy that a PET scanner can detect, producing imaging data that complements MRI findings and improves diagnostic confidence.
From clinical guidelines to commercial reality
Despite FET-PET’s established clinical utility, no FDA-approved product existed in the U.S. until now. The approach has been recommended across multiple international clinical practice guidelines, including:
The Pixclara FDA resubmission, lodged in March 2026, directly addressed the Complete Response Letter received in April 2025 by providing additional data and statistical analysis, clearing the path for today’s approval decision.
- NCCN Guidelines for Central Nervous System Cancers
- European Association of Nuclear Medicine (EANM)
- European Association of Neuro-Oncology (EANO)
- Society of Nuclear Medicine and Molecular Imaging (SNMMI)
- Response Assessment in Neuro-Oncology (RANO) and paediatric equivalents (The European Society for Pediatric Oncology and The Response Assessment in Pediatric Neuro-Oncology)
Guideline endorsement created clinical awareness, but FDA approval creates the commercial infrastructure needed for broad U.S. patient access — a distinction that matters for both physicians and investors.
What the approval means for Telix’s commercial portfolio
Pixclara becomes the third approved product within Telix’s precision diagnostics portfolio, joining Illuccix (commercially available in 22 countries including the U.S.) and Gozellix (FDA-approved for prostate imaging). Together, these products form the foundation of Telix’s commercial franchise, built around the theranostics model: pairing precision diagnostics with targeted therapies to both diagnose and treat disease.
Kevin Richardson, Chief Executive Officer, Telix Precision Medicine
“FDA approval of Pixclara will enable broad access in the U.S. to FET-PET imaging, which is already recognized in international clinical practice guidelines. As the first FDA-approved PET imaging drug for glioma, Pixclara will provide physicians in the U.S. with more certainty in their diagnoses and greater confidence in their treatment planning for patients.”
External stakeholders underscored the clinical significance of the decision. Kelly Sitkin, President and CEO of the American Brain Tumor Association, said: “The approval of Pixclara will advance glioma care by enabling more precise monitoring, complementing the role of MRI. We welcome the FDA’s decision, which provides a pathway to access this technology in the U.S. and helps address a critical unmet need in brain cancer diagnostics.”
Patrick Wen, MD, E. Antonio Chiocca, MD, PhD, Family Endowed Chair in Neuro-Oncology at Mass General Brigham Cancer Institute, added: “Having an FDA-approved FET-PET product with high diagnostic accuracy will make a significant, positive difference to the management of patients with gliomas. This is a very positive step forward for brain cancer imaging and treatment planning.”
A growing theranostics franchise
| Product | Indication | Geography | Status |
|---|---|---|---|
| Illuccix | Prostate imaging | 22 countries (incl. U.S.) | Commercially available |
| Gozellix | Prostate imaging | U.S. | FDA-approved |
| Pixclara | Glioma imaging | U.S. | FDA-approved — September 2026 |
Pipeline depth and the road ahead
The Pixclara approval is not solely a commercial milestone. The same compound (TLX101-Px) is the subject of a Phase 3 registrational study exploring potential indication expansion into the diagnosis of brain metastases, with an Investigational New Drug (IND) application cleared and a Study May Proceed notification received from the FDA in August 2026.
Beyond diagnostics, Telix’s late-stage therapeutic pipeline includes three investigational assets currently in pivotal-stage trials:
- TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) — prostate cancer
- TLX101-Tx (131I-iodofalan) — recurrent glioblastoma
- TLX250-Tx (lutetium (177Lu) girentuximab tetraxetan) — kidney cancer
It is important to note that TLX591-Tx, TLX101-Tx, and TLX250-Tx have not received marketing authorisations in any jurisdiction.
For investors wanting broader financial context behind Telix’s commercial trajectory, our deep-dive into Telix’s Q1 2026 revenue performance covers the US$230 million quarterly result, full-year guidance of US$950 million to US$970 million, and the role of Illuccix and Gozellix in funding pipeline advancement.
The Pixclara approval demonstrates Telix’s ability to navigate the FDA regulatory pathway and translate guideline-endorsed science into approved commercial products. As the therapeutic pipeline matures toward potential future approvals, the company’s track record of regulatory execution across its diagnostics portfolio provides relevant context for assessing that progress.
Don’t Miss the Next ASX Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news straight to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at Big News Blast to start receiving alerts today.